SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after Novo Nordisk filed a lawsuit for alleged patent infringement over its compounded GLP-1 medications, intensifying regulatory pressure from the FDA and DOJ following the company's withdrawal of its oral semaglutide pill. The community is sharply divided between those who see this as a terminal blow to a "copycat" business model and others who view the sell-off as an overreaction, creating a potential "buy the dip" or "short squeeze" opportunity against big pharma.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

ELF Beauty is trending after strong earnings and raised guidance were overshadowed by a market reaction many attribute to a recent Super Bowl commercial. The community is actively discussing this perceived overreaction, with many viewing the subsequent dip as a compelling buying opportunity.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending amid a significant downgrade by JPMorgan, reduced forecasts, a CFO departure, delayed financial filings, and allegations of financial impropriety from a short-seller. This has ignited intense community discussion, with some fearing severe financial issues while others see the sharp valuation drop as an overreaction and a potential buying opportunity.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending after its latest earnings report revealed a revenue miss and net loss, prompting a significant share price drop. Despite an adjusted EPS beat, the community is divided between investors highlighting management's optimistic outlook for 2026, including improving market conditions and strategic partnerships, and skeptics pointing to a history of underperformance and uncertainty around future growth.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending due to its significant all-stock acquisition of Valaris, a move the community largely views as a transformative consolidation poised to enhance market leadership and pricing discipline in the offshore drilling sector. Many anticipate the deal will accelerate debt reduction and position the combined entity for an emerging industry upcycle, though some investors are questioning its immediate impact on existing debt and asset strategy.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum (LITE) is currently trending due to a significant earnings beat and exceptionally strong guidance, fueled by robust demand for its optical components essential for AI data center infrastructure. The community is polarized, with bulls highlighting the company's critical role in the AI build-out and massive analyst upgrades, while bears warn of extreme overvaluation and an inevitable market correction.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending following a mixed earnings report where strong Q4 results were overshadowed by conservative forward guidance, leading to a significant stock decline. This has sparked intense community debate, with some investors viewing the dip as an extreme overreaction and a buying opportunity, while others express concerns about the company's future growth and its position within the competitive software sector amidst rising AI advancements.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as the community highlights significant commitments from Tether for advertising and cloud spending, alongside its strategic acquisition of Northern Data, positioning it as a key AI cloud infrastructure player. Discussion is also centering on record-high short interest and the potential for a short squeeze, further amplified by the return of prominent content creators.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending as Citron Research pounds the table on its leading AI agent security capabilities, specifically highlighting the Prompt Security acquisition as crucial for combating advanced threats like Clawbot. This bullish call, combined with recent GovRamp authorization, sparks lively debate among investors who see deep value at current multi-year lows despite persistent selling pressure and frustration over management.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after Morgan Stanley initiated coverage with an Overweight rating, highlighting its strategic pivot to AI data centers, strong power infrastructure, and deals with major hyperscalers like Google. The community is actively discussing the company's significant growth potential, the increasing disconnect from Bitcoin price action, and the possibility of short squeezes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How Is The Market Feeling About CalciMedica Inc?

<ul class="summary-bullets"><li>According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly with respect to patient enrollment criteria. &nbsp;</li><li>There were no deaths in the trial related to the study drug or any serious adverse events that warranted expedited reporting to the U.S. Food and Drug Administration, the company added.</li><li>Oppenheimer sees the stock as oversold on today's news and "significantly undervalued."</li></ul>CalciMedica (CALC) shares closed down 76% and edged further 4% lower after-hours on Wednesday after the company said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.<h2 class="st-heading-2">Rationale For Discontinuation</h2>The biopharmaceutical company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/calcimedica-announces-discontinuation-of-phase-2-kourage-trial-in-aki-following-independent-data-monitoring-committee-recommendation-302671925.html">said</a> that the discontinuation decision followed a recommendation from an independent data monitoring committee that identified a safety concern.According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly with respect to patient enrollment criteria. &nbsp;There were no deaths in the trial related to the study drug or any serious adverse events that warranted expedited reporting to the U.S. Food and Drug Administration, the company added.CalciMedica will now perform a review of the clinical data, which will inform how evaluation of Auxora will proceed in acute kidney injuries. &nbsp;"Based on the IDMC's feedback, we will review the unblinded KOURAGE data and explore modifications to the trial design, particularly patient enrollment criteria, that may support further clinical testing of Auxora in patients with AKI," said CEO Rachel Leheny.CalciMedica is also evaluating Auxora in acute pancreatitis and severe COVID-19 pneumonia.<h2 class="st-heading-2">Analyst Take</h2>Oppenheimer on Wednesday said that shares of CALC were oversold after the company announced the discontinuation of the mid-stage trial in patients with kidney injury.Oppenheimer said that it caught up with management following the news, who said the safety concern identified by the independent committee's review of unblinded data "appears to stem not from the drug itself, but from aspects of this particular trial."The firm sees the stock as oversold on today's news and "significantly undervalued." Even if one removes any revenue potential in AKI from projections, Auxora's derisked $200M opportunity in acute pancreatitis alone supports a favorable outlook, the analyst said.The firm has an ‘Outperform’ rating on CalciMedica shares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CALC stock jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user voiced hopes for a rebound in share price to sell.<stembedurl>https://www.stocktwits.com/tragusa/message/643195813</stembedurl>Another echoed Oppenheimer and said that the stock is oversold for the news. “This should correct itself either fast or slow but it will correct itself,” they said.<stembedurl>https://www.stocktwits.com/Lay1a/message/643185864</stembedurl><a href="https://stocktwits.com/symbol/CALC">CALC stock</a> has dropped 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-q4-2025-earnings/cmyg0wMR40q">Tesla Shares Rise After Hours As EV Giant Commits To Vehicle Autonomy, AI With Cybercab And $2B xAI Investment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

CALC Stock Slumped 76% On Wednesday — Here’s Why

CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation. 

Equity

CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation. 


CalciMedica (NASDAQ:CALC) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded CalciMedica to a "sell" rating in a report on Saturday...

CalciMedica (NASDAQ:CALC) Trading Down 2.1% - Time to Sell?

CalciMedica (NASDAQ:CALC) Stock Price Down 2.1% - Time to Sell...

Stonepine Capital Management LLC Has $136,000 Stock Position in CalciMedica Inc. $CALC

Stonepine Capital Management LLC lowered its stake in shares of CalciMedica Inc. (NASDAQ:CALC - Free Report) by 76.9% during the second quarter, according to the company in its most recent filing...

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates...

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension CalciMedica Announces Publication in...

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora CalciMedica and Telperian Announce Collaboration to...

CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.

CalciMedica Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$0.6489
Prev Close	$0.6001
Open	$0.6255
Dividend Yield	0.00%
50-Day Moving Average	$4.54
Beta	0.40
Avg. Volume	2.73M
PE Ratio	-0.37

52-Week High	$7.20
52-Week Low	$0.5201
Market Capitalization	$8.65M
EPS (Annual)	-$1.22
Price to Book	-31.92
Revenue Per Employee	$0.00

CALC
CalciMedica Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CALC News

CALCCalciMedica Inc